Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study

• Egile Nagusiak: Chie Masaki (Egilea), Kiminori Sugino (Egilea), Yoshinori Tanizawa (Egilea), Kenichi Nakamura (Egilea), Yui Okada (Egilea), Zhihong Cai (Egilea), Takahiro Okamoto (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequential treatment with MKIs is conducted in Japanese clinical practice is unknown. Methods This retrospective observational cohort study used a J...